Financhill
Buy
68

ETON Quote, Financials, Valuation and Earnings

Last price:
$12.60
Seasonality move :
-5%
Day range:
$12.00 - $12.63
52-week range:
$3.03 - $13.98
Dividend yield:
0%
P/E ratio:
79.75x
P/S ratio:
9.36x
P/B ratio:
20.21x
Volume:
122.3K
Avg. volume:
269K
1-year change:
172.33%
Market cap:
$323M
Revenue:
$31.6M
EPS (TTM):
-$0.22

Analysts' Opinion

  • Consensus Rating
    Eton Pharmaceuticals has received a consensus rating of --. The company's average rating is a -- based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of --, Eton Pharmaceuticals has an estimated upside of 20% from its current price of $12.50.
  • Price Target Downside
    According to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $12.50.

Fair Value

  • According to the consensus of 0 analysts, Eton Pharmaceuticals has 20% upside to fair value with a price target of -- per share.

ETON vs. S&P 500

  • Over the past 5 trading days, Eton Pharmaceuticals has underperformed the S&P 500 by -3.56% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Eton Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Eton Pharmaceuticals has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Eton Pharmaceuticals reported revenues of $10.3M.

Earnings Growth

  • Eton Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Eton Pharmaceuticals reported earnings per share of $0.02.
Enterprise value:
306.8M
EV / Invested capital:
15.26x
Price / LTM sales:
9.36x
EV / EBIT:
129.72x
EV / Revenue:
8.85x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
1,283.75x
Price / Operating cash flow:
1,357.64x
Enterprise value / EBITDA:
47.44x
Gross Profit (TTM):
$20.6M
Return On Assets:
-16.95%
Net Income Margin (TTM):
-15.81%
Return On Equity:
-35.45%
Return On Invested Capital:
-26.81%
Operating Margin:
4.93%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $18.8M $32.8M $34.7M $7M $10.3M
Gross Profit $13.7M $23.8M $20.6M $4.4M $6.3M
Operating Income -$8M $1.9M -$5.2M -$548K $509K
EBITDA -$6.9M $3.5M -$4.9M -$357K $787K
Diluted EPS -$0.35 $0.10 -$0.22 -$0.02 $0.02
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $9.8M $25.9M $16.4M $27.2M $29.7M
Total Assets $11.4M $26.6M $21.5M $31.5M $35.8M
Current Liabilities $3.2M $5.4M $4.7M $10.4M $19.7M
Total Liabilities $10M $10.9M $10.3M $14.6M $19.9M
Total Equity $1.4M $15.7M $11.2M $16.9M $16M
Total Debt $7M $6.6M $6.4M $5.7M $4.1M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$3.1M $9.3M $2.1M $873K $3M
Cash From Investing -$6M -$12K -$2.7M -- --
Cash From Financing -$165K -$564K -$1.3M -$369K -$385K
Free Cash Flow -$9.2M $9.3M $239K $873K $3M
ETON
Sector
Market Cap
$323M
$45.6M
Price % of 52-Week High
89.41%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
172.33%
-31.35%
Beta (5-Year)
1.394
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $12.40
200-day SMA
Buy
Level $5.63
Bollinger Bands (100)
Buy
Level 4.6 - 10.78
Chaikin Money Flow
Buy
Level 4.1M
20-day SMA
Buy
Level $12.40
Relative Strength Index (RSI14)
Buy
Level 59.46
ADX Line
Buy
Level 15.71
Williams %R
Neutral
Level -47.8788
50-day SMA
Buy
Level $10.38
MACD (12, 26)
Buy
Level 0.59
25-day Aroon Oscillator
Buy
Level 36
On Balance Volume
Neutral
Level 30.7M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (0.8343)
Buy
CA Score (Annual)
Level (-0.2027)
--
Beneish M-Score (Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (6.2749)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

Stock Forecast FAQ

In the current month, ETON has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ETON average analyst price target in the past 3 months is --.

  • Where Will Eton Pharmaceuticals Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Eton Pharmaceuticals share price will rise to -- per share over the next 12 months.

  • What Do Analysts Say About Eton Pharmaceuticals?

    Analysts are divided on their view about Eton Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Eton Pharmaceuticals is a Sell and believe this share price will drop from its current level to --.

  • What Is Eton Pharmaceuticals's Price Target?

    The price target for Eton Pharmaceuticals over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is ETON A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Eton Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.

  • How Can I Buy Shares Of ETON?

    You can purchase shares of Eton Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Eton Pharmaceuticals shares.

  • What Is The Eton Pharmaceuticals Share Price Today?

    Eton Pharmaceuticals was last trading at $12.60 per share. This represents the most recent stock quote for Eton Pharmaceuticals. Yesterday, Eton Pharmaceuticals closed at $12.50 per share.

  • How To Buy Eton Pharmaceuticals Stock Online?

    In order to purchase Eton Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Is Tesla Going to Buy Uber?
Is Tesla Going to Buy Uber?

Tesla has always been in the habit of making large,…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
52
TSLL alert for Dec 24

Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.

Buy
73
PSIX alert for Dec 24

Power Solutions International [PSIX] is up 27.42% over the past day.

Sell
31
SOXL alert for Dec 24

Direxion Daily Semiconductor Bull 3X Shares [SOXL] is up 11.87% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock